Role of Niemann-Pick C1-Like 1 (NPC1L1) in Intestinal Sterol Absorption

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Absorption of cholesterol by the proximal small intestine represents a major pathway for entry of cholesterol into the body pools. This cholesterol is derived primarily from the bile and diet. In adult humans, typically several hundred milligrams of cholesterol reach the liver from the intestine daily, with the potential to impact the plasma low-density lipoprotein cholesterol (LDL-C) concentration. There are three main phases involved in cholesterol absorption. The first occurs intraluminally and culminates in micellar solubilization of unesterified cholesterol, which facilitates its movement up to the brush border membrane (BBM) of the enterocyte. The second phase involves transport of cholesterol across the BBM by Niemann-Pick C1 Like-1 (NPC1L1), whereas the third phase entails a series of steps within the enterocyte involving esterification of cholesterol and its incorporation, along with other lipids and apolipoprotein B-48, into nascent chylomicrons. Discovery of the role of NPC1L1 in intestinal sterol transport occurred directly as a consequence of efforts to identify the molecular target of ezetimibe, a novel, potent, and specific inhibitor of sterol absorption that is now widely used in combination therapy with statins for management of hypercholesterolemia in the general population. Some aspects of the role of NPC1L1 in cholesterol absorption nevertheless remain controversial and are the subject of ongoing research. For example, one report suggests that NPC1L1 is located not in the plasma membrane, but intracellularly, where it is believed to be involved in cytosolic trafficking of cholesterol, whereas another concludes that a protein other than NPC1L1 is responsible for the high-affinity binding of cholesterol on intestinal BBM. However, other new studies that show that in vivo responsiveness of different species to ezetimibe correlates with NPC1L1 binding affinity further support the widely held belief that NPC1L1 does facilitate sterol uptake by the enterocyte and is the target of ezetimibe. Added to this is the unequivocal finding that deletion of the gene for NPC1L1 in mice results in near complete prevention of cholesterol absorption and an accelerated rate of fecal neutral sterol excretion. In summary, the development of ezetimibe and the identification of NPC1L1 as a key player in sterol absorption have taken research on the molecular control of this pathway to an exciting new level. From this, it is hoped that we will now be able to determine more precisely what effect, if any, other classes of lipid-lowering agents, particularly the statins, might exert on the amount of intestinal cholesterol reaching the liver.

Original languageEnglish (US)
JournalJournal of Clinical Lipidology
Volume2
Issue number2
DOIs
StatePublished - Apr 2008

Fingerprint

Intestinal Absorption
Sterols
Cholesterol
Enterocytes
Microvilli
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Membranes
Apolipoprotein B-48
Lipids
Chylomicrons
Esterification
Liver
Gene Deletion
Hypercholesterolemia
Research
Bile
LDL Cholesterol
Small Intestine
Intestines
Cell Membrane

Keywords

  • Apolipoprotein B-48
  • Brush border membrane
  • Cholesterol synthesis
  • Cholesterol transport
  • Chylomicron cholesterol
  • Enterocyte
  • Fractional cholesterol absorption
  • LDL cholesterol
  • Phytosterol
  • Statin monotherapy
  • Sterol efflux
  • Sterol uptake

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Nutrition and Dietetics

Cite this

Role of Niemann-Pick C1-Like 1 (NPC1L1) in Intestinal Sterol Absorption. / Turley, Stephen D.

In: Journal of Clinical Lipidology, Vol. 2, No. 2, 04.2008.

Research output: Contribution to journalArticle

@article{2bb496ef93d44e1ab2b6664b956f86d7,
title = "Role of Niemann-Pick C1-Like 1 (NPC1L1) in Intestinal Sterol Absorption",
abstract = "Absorption of cholesterol by the proximal small intestine represents a major pathway for entry of cholesterol into the body pools. This cholesterol is derived primarily from the bile and diet. In adult humans, typically several hundred milligrams of cholesterol reach the liver from the intestine daily, with the potential to impact the plasma low-density lipoprotein cholesterol (LDL-C) concentration. There are three main phases involved in cholesterol absorption. The first occurs intraluminally and culminates in micellar solubilization of unesterified cholesterol, which facilitates its movement up to the brush border membrane (BBM) of the enterocyte. The second phase involves transport of cholesterol across the BBM by Niemann-Pick C1 Like-1 (NPC1L1), whereas the third phase entails a series of steps within the enterocyte involving esterification of cholesterol and its incorporation, along with other lipids and apolipoprotein B-48, into nascent chylomicrons. Discovery of the role of NPC1L1 in intestinal sterol transport occurred directly as a consequence of efforts to identify the molecular target of ezetimibe, a novel, potent, and specific inhibitor of sterol absorption that is now widely used in combination therapy with statins for management of hypercholesterolemia in the general population. Some aspects of the role of NPC1L1 in cholesterol absorption nevertheless remain controversial and are the subject of ongoing research. For example, one report suggests that NPC1L1 is located not in the plasma membrane, but intracellularly, where it is believed to be involved in cytosolic trafficking of cholesterol, whereas another concludes that a protein other than NPC1L1 is responsible for the high-affinity binding of cholesterol on intestinal BBM. However, other new studies that show that in vivo responsiveness of different species to ezetimibe correlates with NPC1L1 binding affinity further support the widely held belief that NPC1L1 does facilitate sterol uptake by the enterocyte and is the target of ezetimibe. Added to this is the unequivocal finding that deletion of the gene for NPC1L1 in mice results in near complete prevention of cholesterol absorption and an accelerated rate of fecal neutral sterol excretion. In summary, the development of ezetimibe and the identification of NPC1L1 as a key player in sterol absorption have taken research on the molecular control of this pathway to an exciting new level. From this, it is hoped that we will now be able to determine more precisely what effect, if any, other classes of lipid-lowering agents, particularly the statins, might exert on the amount of intestinal cholesterol reaching the liver.",
keywords = "Apolipoprotein B-48, Brush border membrane, Cholesterol synthesis, Cholesterol transport, Chylomicron cholesterol, Enterocyte, Fractional cholesterol absorption, LDL cholesterol, Phytosterol, Statin monotherapy, Sterol efflux, Sterol uptake",
author = "Turley, {Stephen D.}",
year = "2008",
month = "4",
doi = "10.1016/j.jacl.2008.01.008",
language = "English (US)",
volume = "2",
journal = "Journal of Clinical Lipidology",
issn = "1933-2874",
publisher = "Elsevier BV",
number = "2",

}

TY - JOUR

T1 - Role of Niemann-Pick C1-Like 1 (NPC1L1) in Intestinal Sterol Absorption

AU - Turley, Stephen D.

PY - 2008/4

Y1 - 2008/4

N2 - Absorption of cholesterol by the proximal small intestine represents a major pathway for entry of cholesterol into the body pools. This cholesterol is derived primarily from the bile and diet. In adult humans, typically several hundred milligrams of cholesterol reach the liver from the intestine daily, with the potential to impact the plasma low-density lipoprotein cholesterol (LDL-C) concentration. There are three main phases involved in cholesterol absorption. The first occurs intraluminally and culminates in micellar solubilization of unesterified cholesterol, which facilitates its movement up to the brush border membrane (BBM) of the enterocyte. The second phase involves transport of cholesterol across the BBM by Niemann-Pick C1 Like-1 (NPC1L1), whereas the third phase entails a series of steps within the enterocyte involving esterification of cholesterol and its incorporation, along with other lipids and apolipoprotein B-48, into nascent chylomicrons. Discovery of the role of NPC1L1 in intestinal sterol transport occurred directly as a consequence of efforts to identify the molecular target of ezetimibe, a novel, potent, and specific inhibitor of sterol absorption that is now widely used in combination therapy with statins for management of hypercholesterolemia in the general population. Some aspects of the role of NPC1L1 in cholesterol absorption nevertheless remain controversial and are the subject of ongoing research. For example, one report suggests that NPC1L1 is located not in the plasma membrane, but intracellularly, where it is believed to be involved in cytosolic trafficking of cholesterol, whereas another concludes that a protein other than NPC1L1 is responsible for the high-affinity binding of cholesterol on intestinal BBM. However, other new studies that show that in vivo responsiveness of different species to ezetimibe correlates with NPC1L1 binding affinity further support the widely held belief that NPC1L1 does facilitate sterol uptake by the enterocyte and is the target of ezetimibe. Added to this is the unequivocal finding that deletion of the gene for NPC1L1 in mice results in near complete prevention of cholesterol absorption and an accelerated rate of fecal neutral sterol excretion. In summary, the development of ezetimibe and the identification of NPC1L1 as a key player in sterol absorption have taken research on the molecular control of this pathway to an exciting new level. From this, it is hoped that we will now be able to determine more precisely what effect, if any, other classes of lipid-lowering agents, particularly the statins, might exert on the amount of intestinal cholesterol reaching the liver.

AB - Absorption of cholesterol by the proximal small intestine represents a major pathway for entry of cholesterol into the body pools. This cholesterol is derived primarily from the bile and diet. In adult humans, typically several hundred milligrams of cholesterol reach the liver from the intestine daily, with the potential to impact the plasma low-density lipoprotein cholesterol (LDL-C) concentration. There are three main phases involved in cholesterol absorption. The first occurs intraluminally and culminates in micellar solubilization of unesterified cholesterol, which facilitates its movement up to the brush border membrane (BBM) of the enterocyte. The second phase involves transport of cholesterol across the BBM by Niemann-Pick C1 Like-1 (NPC1L1), whereas the third phase entails a series of steps within the enterocyte involving esterification of cholesterol and its incorporation, along with other lipids and apolipoprotein B-48, into nascent chylomicrons. Discovery of the role of NPC1L1 in intestinal sterol transport occurred directly as a consequence of efforts to identify the molecular target of ezetimibe, a novel, potent, and specific inhibitor of sterol absorption that is now widely used in combination therapy with statins for management of hypercholesterolemia in the general population. Some aspects of the role of NPC1L1 in cholesterol absorption nevertheless remain controversial and are the subject of ongoing research. For example, one report suggests that NPC1L1 is located not in the plasma membrane, but intracellularly, where it is believed to be involved in cytosolic trafficking of cholesterol, whereas another concludes that a protein other than NPC1L1 is responsible for the high-affinity binding of cholesterol on intestinal BBM. However, other new studies that show that in vivo responsiveness of different species to ezetimibe correlates with NPC1L1 binding affinity further support the widely held belief that NPC1L1 does facilitate sterol uptake by the enterocyte and is the target of ezetimibe. Added to this is the unequivocal finding that deletion of the gene for NPC1L1 in mice results in near complete prevention of cholesterol absorption and an accelerated rate of fecal neutral sterol excretion. In summary, the development of ezetimibe and the identification of NPC1L1 as a key player in sterol absorption have taken research on the molecular control of this pathway to an exciting new level. From this, it is hoped that we will now be able to determine more precisely what effect, if any, other classes of lipid-lowering agents, particularly the statins, might exert on the amount of intestinal cholesterol reaching the liver.

KW - Apolipoprotein B-48

KW - Brush border membrane

KW - Cholesterol synthesis

KW - Cholesterol transport

KW - Chylomicron cholesterol

KW - Enterocyte

KW - Fractional cholesterol absorption

KW - LDL cholesterol

KW - Phytosterol

KW - Statin monotherapy

KW - Sterol efflux

KW - Sterol uptake

UR - http://www.scopus.com/inward/record.url?scp=40649098464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40649098464&partnerID=8YFLogxK

U2 - 10.1016/j.jacl.2008.01.008

DO - 10.1016/j.jacl.2008.01.008

M3 - Article

VL - 2

JO - Journal of Clinical Lipidology

JF - Journal of Clinical Lipidology

SN - 1933-2874

IS - 2

ER -